glp 1 dizzy Balance Disorders Archives GLP-1 Side Effects – New
Description
In SURMOUNT-1, 72 weeks of tirzepatide induced mean WL of 1622.5% in people without diabetes compared to 2.4% with placebo, with no sign of the weight plateauing, suggesting that there may be further WL with long-term use [46]

In this study, 4076 patients living with T2DM and either a history of CVD (90%) or kidney disease and at least one other cardiovascular risk factor were randomized to receive once-weekly 4 mg or 6 mg efpeglenatide injection or placebo (median follow-up 1.81 years)
Ill share it with you as soon as I find it
The SURMOUNT 4 is a trial to assess the effects of tirzepatide, a dual receptor agonist targeting GLP-1 and GIP, on long-term weight reduction over 2 years in those without diabetes

Ipamorelin Known for its minimal side effects, Ipamorelin works well when combined with CJC-1295 to maximize results without increasing hunger
